Literature DB >> 11166849

Incomplete cross tolerance and multiple mu opioid peptide receptors.

G W Pasternak1.   

Abstract

Clinicians have long known about incomplete cross tolerance and other pharmacological differences among analgesics that act at the mu opioid peptide (MOP) receptor (previously termed MOR). How might drugs that act through the same receptor differ so markedly? One explanation could be the presence of multiple MOP receptor subtypes, as implied from animal models over the past 20 years. More recently, at least seven different MOP receptor splice variants have been isolated. Each variant selectively binds morphine and other drugs that act at the MOP receptor with high affinity. Both antisense and knockout paradigms indicate that MOP-receptor-mediated analgesia involves more than one MOP receptor splice variant. Thus, incomplete cross tolerance among MOP receptor ligands might reflect their differing selectivities for these MOP receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166849     DOI: 10.1016/s0165-6147(00)01616-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  41 in total

1.  Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene.

Authors:  Y X Pan; J Xu; L Mahurter; E Bolan; M Xu; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  [Are polymorphisms in the mu-opioid receptor important for opioid therapy?].

Authors:  J Lötsch; R Freynhagen; G Geisslinger
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

Review 3.  Role of morphine's metabolites in analgesia: concepts and controversies.

Authors:  Erica Wittwer; Steven E Kern
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

Review 4.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

5.  Effects of transgene-mediated endomorphin-2 in inflammatory pain.

Authors:  Shuanglin Hao; Darren Wolfe; Joseph C Glorioso; Marina Mata; David J Fink
Journal:  Eur J Pain       Date:  2008-06-24       Impact factor: 3.931

6.  Mechanisms of inhibitory action of TRK-130 (Naltalimide), a μ-opioid receptor partial agonist, on the micturition reflex.

Authors:  Morihiro Fujimura; Naoki Izumimoto; Sayoko Kanie; Ryosuke Kobayashi; Satoru Yoshikawa; Shinobu Momen; Mikito Hirakata; Toshikazu Komagata; Satoshi Okanishi; Masashi Iwata; Tadatoshi Hashimoto; Takayuki Doi; Naoki Yoshimura; Koji Kawai
Journal:  Int Urol Nephrol       Date:  2017-01-16       Impact factor: 2.370

Review 7.  Indications for Opioid Antagonists.

Authors:  O J Michael Coppes; Christine N Sang
Journal:  Curr Pain Headache Rep       Date:  2017-06

Review 8.  Preclinical pharmacology and opioid combinations.

Authors:  Gavril W Pasternak
Journal:  Pain Med       Date:  2012-03       Impact factor: 3.750

9.  Bioinformatic analysis of the human mu opioid receptor (OPRM1) splice and polymorphic variants.

Authors:  Lili Xin; Zaijie Jim Wang
Journal:  AAPS PharmSci       Date:  2002

Review 10.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.